RAY HORWITZ: Open Payments
NPI 1376640953 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,418 in 55 payments from 14 companies in 2025. Trend: 2023 $20,636 · 2024 $17,707 · 2025 $1,418
Food & beverage: $1,418
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 5 | $272 |
| Axsome Therapeutics, Inc. | 6 | $253 |
| Vanda Pharmaceuticals Inc. | 14 | $240 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $135 |
| Supernus Pharmaceuticals, Inc. | 1 | $111 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Lundbeck LLC | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Alkermes, Inc. | 2 | $40 |
| Corium, LLC | 2 | $39 |
Products named: SPRAVATO, Auvelity, FANAPT, REXULTI, CAPLYTA, Qelbree, TRINTELLIX, ARISTADA.
Industry payments across GA — which companies pay providers there.
